HealthQuill Aliada Therapeutics
AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.
Drugs Health Pharma

AbbVie says schizophrenic drug fails in 2 mid-stage experimental trials

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

Read More
AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as Alzheimer’s disease, for $1.4 billion in cash.
Drugs Health Pharma

AbbVie to acquire Aliada for $1.4 billion, bags Alzheimer’s therapy 

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.

Read More